Volume 27, Number 2—February 2021
Dispatch
Murine Typhus in Canary Islands, Spain, 1999–2015
Table 2
Finding | No. (%) | IgM >1:1,280, no. (%)† | 4-fold IgG titer increase, no. (%)‡ | p-value | Cutoff values |
---|---|---|---|---|---|
Anemia, n = 220 | 38 (17.3) | 16 (22.5) | 22 (14.8) | 0.15 | <12 g/dL Hb in women, <13 g/dL Hb in men |
Leukopenia, n = 220 | 23 (10.5) | 7 (9.9) | 16 (10.7) | 0.26 | <4,000/μL |
Leukocytosis, n = 220 | 42 (19.1) | 18 (25.4) | 24 (16.1) | 0.26 | >11,000/μL |
Thrombocytopenia, n = 218 | 127 (58.3) | 28 (39.4) | 99 (67.3) | <0.01 | <150,000/μL |
Increased ESR, n = 106 | 64 (60.4) | 27 (65.9) | 37 (56.9) | 0.42 | Upper limit of normality calculated according to age and sex |
Prolonged PT, n = 197 | 82 (41.6) | 27 (42.9) | 55 (41) | 0.81 | <80% |
Increased aPTTr, n = 188 | 6 (3.2) | 2 (3.4) | 4 (3.1) | 0.99 | >1.2 |
Plasma Cr increase, n = 215 | 47 (21.9) | 16 (23.5) | 31 (21.1) | 0.72 | >1.2 mg/dL |
Hyponatremia, n = 205 | 119 (58) | 30 (50) | 89 (61.4) | 0.13 | <135 mEq/L |
Plasma CK increase, n = 97 | 20 (20.6) | 5 (13.5) | 15 (25) | 0.17 | >232 U/L |
Plasma urea increase, n = 211 | 36 (17.1) | 12 (18.5) | 24 (16.4) | 0.72 | >40 mg/dL |
Plasma LDH increase, n = 138 | 131 (94.9) | 40 (90.9) | 91 (96.8) | 0.21 | >190 U/L |
Plasma ALT increase, n = 197 | 184 (93.4) | 59 (92.2) | 125 (94) | 0.76 | >35 U/L |
Plasma AST increase, n = 196 | 182 (92.9) | 55 (88.7) | 127 (94.81) | 0.14 | >35 U/L |
Plasma AP increase, n = 109 | 38 (34.9) | 10 (25.6) | 28 (40) | 0.15 | >136 U/L |
Plasma GGT increase, n = 166 | 91 (54.8) | 29 (52.7) | 62 (55.9) | 0.74 | >85 U/L |
Microhematuria, n = 195 | 146 (74.9) | 45 (72.6) | 101 (75.9) | 0.6 | >5 RBCs/mm3 |
Proteinuria, n = 195 | 169 (86.7) | 54 (87.1) | 115 (86.5) | 0.9 | Positive urine test strip |
Leukocyturia, n = 194 | 123 (63.4) | 38 (62.3) | 85 (63.9) | 0.83 | >10 WBCs/mm3 |
*ALT, alanine aminotransferase; AP, alkaline phosphatase; aPTTr, activated partial thromboplastin time ratio; AST, aspartate aminotransferase; Cr, creatinine; CK, creatine kinase; ESR, erythrocyte sedimentation rate; GGT, γ-glutamyl transpeptidase; Hb, hemoglobin; LDH, lactate dehydrogenase; PT, prothrombin Time; RBCs, red blood cells; WBCs, white blood cells. †Patients given a diagnosis by testing of 1 sample (criterion 1). ‡Patients given a diagnosis by testing of 2 consecutive samples (criterion 2).
Page created: October 13, 2020
Page updated: January 24, 2021
Page reviewed: January 24, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.